| R-MVST Cells for Treatment of Viral Infections (NCT05183490) | Columbia University | 2022-05-03 |
| Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant (NCT05305040) | AlloVir | 2022-03-24 |
| Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft (NCT04989491) | University Hospital, Strasbourg, France | 2021-12-01 |
| Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant (NCT04693637) | AlloVir | 2021-01-15 |
| Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial (NCT04507477) | University Health Network, Toronto | 2020-07-07 |
| EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection (NCT03266653) | New York Medical College | 2020-07-07 |
| Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas (NCT03258567) | National Cancer Institute (NCI) | 2018-04-26 |
| Immunodeficiency for Severe Epstein-Barr Virus Infection (NCT03374566) | Children's Hospital of Fudan University | 2017-12-01 |
| Early Detection of Epstein-Barr Virus Related Disease. (NCT03546101) | University of Aarhus | 2017-11-01 |
| Study on Infectious Mononucleosis in Munich (NCT06002802) | Technical University of Munich | 2016-03-01 |
| A Study of the Safety and Efficacy of EBV Specific T-cell Lines (NCT02580539) | Dr. Jean-Sebastien Delisle, MD, PhD | 2015-11-01 |
| Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents (NCT02335437) | University Hospital, Akershus | 2015-03-01 |
| ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation (NCT01972035) | University of Minnesota | 2014-08-01 |
| A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma (NCT01800071) | Cancer Research UK | 2013-03-01 |
| Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV (NCT01535885) | Medical College of Wisconsin | 2012-02-01 |
| Bortezomib Plus Rituximab for EBV+ PTLD (NCT01058239) | Massachusetts General Hospital | 2011-11-01 |
| Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) (NCT01070797) | Baylor College of Medicine | 2011-01-01 |
| The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis (NCT01248598) | Rambam Health Care Campus | 2010-10-01 |
| Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy (NCT01094405) | Chinese University of Hong Kong | 2010-03-31 |
| Modified Vaccinia Ankara (MVA) Vaccine Study (NCT01256853) | Chinese University of Hong Kong | 2006-09-01 |
| Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations (NCT00070785) | National Institutes of Health Clinical Center (CC) | 2003-10-06 |
| EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients (NCT00963248) | Klinik für Kinder- und Jugendmedizin | 2003-07-01 |
| Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). (NCT00058604) | Baylor College of Medicine | 2001-01-01 |
| Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) (NCT00058591) | Baylor College of Medicine | 2000-01-01 |
| Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts (NCT00058812) | Baylor College of Medicine | 1993-05-01 |